NovaBridge Biosciences
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at NovaBridge Biosciences.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 1.40 $ to 6.60 $ · Last price: 1.40 $ (As of: September 28, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/29/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| NovaBridge Biosciences NBP | 0.2 | – | 0.1 | – | 0.0 | – | -60.9 |
| Vertex Pharmaceuticals Inc VRTX | 133.5 | 32.0 | 24.4 | 55.0 | 38.1 | 9.6 | 36.8 |
| Moderna Inc MRNA | 78.3 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| Regeneron Pharmaceuticals Inc REGN | 78.2 | 18.9 | 13.5 | 44.5 | 20.7 | 1.0 | 34.1 |
| argenx NV ARGX | 60.5 | 37.2 | 30.7 | 59.1 | 32.0 | 89.6 | 36.6 |
| Revolution Medicines Inc RVMD | 41.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.3 |
| BeiGene, Ltd. ONC | 41.5 | 65.5 | 32.4 | 88.9 | 19.1 | 40.2 | 12.6 |
| Alnylam Pharmaceuticals Inc ALNY | 33.9 | 64.3 | 28.6 | 79.7 | 23.0 | 65.2 | -42.8 |
| Royalty Pharma Plc RPRX | 32.2 | 31.5 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 41.9 | 34.6 | 19.2 | 57.0 | 20.7 | 7.3 | 36.6 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 11 | -274 | -298 | -5.13 | -252 | 410 | 1,025 |
| 2018 | 54 | -456 | -403 | -6.92 | -281 | -955 | 2,376 |
| 2019 | 30 | -1,465 | -1,448 | -24.89 | -868 | 1,069 | 1,738 |
| 2020 | 1,543 | 156 | 471 | 6.89 | 434 | 5,627 | 6,334 |
| 2021 | 88 | -2,071 | -2,332 | -30.69 | -973 | 715 | 879 |
| 2022 | -11 | -366 | -968 | -11.73 | -1,103 | 3,008 | 4,074 |
| 2023 | 4 | -511 | -1,466 | -17.61 | -73 | 243 | 369 |
| 2024 | 0 | -375 | -162 | -2.00 | -384 | 1,468 | 1,552 |
| 2025 | 0 | -13 | -7 | -0.16 | -21 | 33 | 37 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2023: Q3 | – | – | -31 | 77.70 | – | – | – |
| 2024: Q1 | – | – | 1 | -88.40 | 1,835.20 | – | – |
| 2024: Q2 | 0.30 | – | 72 | 628.90 | -46.10 | – | – |
| 2024: Q3 | -0.11 | – | 0 | 100.00 | – | 8 | 8 |
| 2025: Q1 | -0.04 | – | 0 | -100.00 | – | – | – |
| 2025: Q2 | -0.07 | -123.30 | 0 | -100.00 | – | – | – |
| 2025: Q3 | -0.06 | 45.50 | 238 | – | -2.90 | 13 | 13 |
| 2025: Q4 | -0.31 | -416.70 | 0 | – | – | -15 | -15 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.91 | -0.91 – -0.91 | 0 | -95.8% | 1 |
| 12/31/2027 | -0.63 | -0.63 – -0.63 | 0 | -12.8% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -100.0%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -20.0%
- ROCE > 15% -40.4%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Dennis Phillip Andrew | Chief Medical Officer | Sell | 8,209 | 0.71 | 5,828 |
| Sep 17, 2026 | Dennis Phillip Andrew | Chief Medical Officer | Other | 23,695 | – | – |
| Sep 9, 2026 | Cao Sean Wuxiong | Chief Bus. Development Officer | Sell | 107,978 | 0.74 | 79,904 |
| Sep 3, 2026 | Cao Sean Wuxiong | Chief Bus. Development Officer | Other | 104,236 | – | – |
| Sep 3, 2026 | Cao Sean Wuxiong | Chief Bus. Development Officer | Other | 235,136 | – | – |
| Aug 31, 2026 | Xu Cong Claire | EVP, Clinical Development | Sell | 3,282 | 0.79 | 2,593 |
| Aug 30, 2026 | Xu Cong Claire | EVP, Clinical Development | Other | 9,382 | – | – |
| Aug 22, 2026 | Lenz Robert A. | Director | Other | 17,218 | – | – |
The company
About the Company
NovaBridge Biosciences, ein Biotechnologieunternehmen, betreibt Forschung und Entwicklung immunonkologischer Wirkstoffe zur Krebsbehandlung in den Vereinigten Staaten. Das Unternehmen ist in zwei Segmenten tätig: Onkologie und Ophthalmologie. Seine Produktpipeline umfasst Givastomig, einen potenziellen bispezifischen CLDN18.2-Antikörper, der sich in einer Phase-2-Studie in Kombination mit Nivolumab und Chemotherapie zur Behandlung von Magenkrebs und anderen CLDN18.2-positiven Magen-Darm-Malignomen befindet, sowie in einer Phase-1b-Studie in Kombination mit Nivolumab und Chemotherapie bei Magenkrebs in der Erstlinientherapie. Das Unternehmen entwickelt zudem VIS-101, ein bispezifisches VEGF-A-x-ANG-2-Biologikum in Phase-2-Studie zur Behandlung der feuchten altersbedingten Makuladegeneration und anderer Netzhauterkrankungen einschließlich des diabetischen Makulaödems, sowie Ragistomag, das sich in einer Phase-1-Studie bei verschiedenen soliden Tumoren befindet. Es hat eine Lizenzvereinbarung mit AskGene zur Entwicklung und Vermarktung von VIS-101, eine Zusammenarbeit mit Bristol Myers Squibb zur Entwicklung von Givastomig sowie eine Lizenz- und Kooperationsvereinbarung mit der AbbVie Ireland Unlimited Company zur Entwicklung und Vermarktung von Lemzoparlimab. Das Unternehmen hieß früher I-Mab und änderte seinen Namen im Oktober 2025 in NovaBridge Biosciences. NovaBridge Biosciences wurde 2014 gegründet und hat seinen Hauptsitz in Rockville, Maryland.
- Employees
- 30
- Headquarters
- Rockville, MD
- Address
- 2440 Research Boulevard, 20850 Rockville, United States
- Phone
- 240 745 6330
- Website
- novabridge.com
- IPO Date
- 01/17/2020
- ISIN
- US44975P1030
Management
| Name | Title | Birth Year |
|---|---|---|
| Wei Fu | Executive Chairman | 1982 |
| Ming Lei | Chief Financial Officer | 1997 |
| Sean Wuxiong Cao M.B.A., Ph.D. | Chief Business Development Officer & Director | 1967 |
| Srishti Gupta M.D. | CEO & Director | 1976 |
| Mark Hagler | President & Chief Commercial Officer | – |
| Tyler Ehler | Senior Director of Investor Relations | – |
| Liwei Lin | General Counsel & Board Secretary | 1988 |
| Cong Xu M.D., Ph.D. | Senior VP and Head of R&D Center of Excellence | 1985 |
| Phillip Dennis M.D., Ph.D. | Chief Medical Officer | 1963 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.